Connor, Clark & Lunn Investment Management Ltd. Enanta Pharmaceuticals Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 11,768 shares of ENTA stock, worth $73,903. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,768
Holding current value
$73,903
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
$10.05 - $16.54 $118,268 - $194,642
11,768 New
11,768 $122,000
Q1 2024

May 09, 2024
BUY
$10.08 - $17.46 $32,901 - $56,989
3,264 Added 7.89%
44,629 $779,000
Q4 2023

Feb 09, 2024
BUY
$8.18 - $10.78 $338,365 - $445,914
41,365 New
41,365 $389,000
Q3 2022

Nov 10, 2022
BUY
$48.29 - $71.27 $246,761 - $364,189
5,110 New
5,110 $265,000
Q3 2020

Nov 12, 2020
SELL
$43.36 - $53.53 $429,740 - $530,535
-9,911 Closed
0 $0
Q2 2020

Aug 13, 2020
BUY
$46.37 - $57.58 $459,573 - $570,675
9,911 New
9,911 $498,000
Q4 2019

Feb 12, 2020
SELL
$57.95 - $66.61 $460,702 - $529,549
-7,950 Closed
0 $0
Q3 2019

Nov 13, 2019
BUY
$60.08 - $88.17 $318,424 - $467,301
5,300 Added 200.0%
7,950 $478,000
Q2 2019

Aug 07, 2019
BUY
$81.3 - $97.35 $215,445 - $257,977
2,650 New
2,650 $224,000
Q1 2019

May 08, 2019
SELL
$69.08 - $105.66 $214,148 - $327,546
-3,100 Closed
0 $0
Q4 2018

Feb 12, 2019
SELL
$65.41 - $84.65 $78,492 - $101,580
-1,200 Reduced 27.91%
3,100 $220,000
Q3 2018

Nov 13, 2018
BUY
$85.46 - $126.37 $367,478 - $543,391
4,300 New
4,300 $367,000

Others Institutions Holding ENTA

# of Institutions
110
Shares Held
21.1M
Call Options Held
4.8K
Put Options Held
4.6K
View Full List

About ENANTA PHARMACEUTICALS INC

ENTA Quotes by TradingView
  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $130M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email